Open Label, Phase 2 Study for Evaluating the Feasibility, Safety and Efficacy of Psychotherapy Assisted Psilocybin for Treatment of Severe Obsessive Compulsive Disorder (OCD) in Drug and/or Psychotherapy Resistant Patients.
Phase: PHASE2 | Sponsor: Beersheva Mental Health Center | Compound: Psilocybin
- Status
- recruiting
- Institution
- Beersheva Mental Health Center
- Start date
- 2024-11-25
- End date
- 2027-06-01
- Registry ID
- NCT04882839
Tracked by the DMT Code Clinical Trials Observatory, an open record of DMT-related clinical research.